Executive overhaul at pharmaceuticals giant

Pharma giant GSK has announced an overhaul of its executive team.

The group – which operates a major vaccines plant at Montrose in Angus – confirmed to the London Stock Exchange that Luc Debruyne, president of the vaccines operation, is to leave GSK at the end of the year, after a career spanning 27 years.

In his most recent role, Mr Debruyne has overseen the successful integration of the Novartis vaccines business into GSK’s portfolio.

Roger Connor, who is currently president of GSK’s global manufacturing and supply operation, will take up Mr Debruyne’s role from September 1.

From the same date, Regis Simard will become GSK’s president of pharmaceutical supply chain and will take a seat on the group’s corporate executive team

He joined GSK in 2005 and is senior vice-president of global pharma manufacturing.

He previously worked in electronics, medical devices and the pharmaceutical industries.